Aptus Pharma Ipo
Aptus Pharma IPO Review & Key Points
Review:
IPO Lead Managers aka Merchant Bankers
Interactive Financial Services Ltd.
| Application | Lot Size | Shares | Amount |
| Retail Minimum | 2 | 4,000 | ₹2,80,000 |
| Retail Maximum | 2 | 4,000 | ₹2,80,000 |
| S-HNI Minimum | 3 | 6,000 | ₹4,20,000 |
| S-HNI Maximum | 7 | 14,000 | ₹9,80,000 |
| B-HNI Minimum | 8 | 16,000 | ₹11,20,000 |
| Investor Category | Share Offered | % Shares |
| Market Maker Shares Offered | 94,000 Shares | 5.05% |
| QIB Shares Offered | 8,80,000 Shares | 47.31% |
| Anchor Investor | 5,28,000 Shares | 28.39% |
| QIB (Ex. Anchor) | 3,52,000 Shares | 18.92% |
| NII Shares Offered | 2,66,000 Shares | 14.30% |
| bNII > ₹10L | – Shares | -% |
| sNII < ₹10L | – Shares | -% |
| Retail Shares Offered | 6,20,000 Shares | 33.33% |
| Anchor Bidding Date | September 22, 2025 |
| Anchor Investors List | |
| Shares Offered | 5,28,000 Shares |
| Anchor Size | 3.70 Cr. |
| lock-in period end date 50% shares (30 Days) | October 26, 2025 |
| lock-in period end date 50% shares (90 Days) | December 25, 2025 |
| IPO Open Date: | September 23, 2025 |
| IPO Close Date: | September 25, 2025 |
| Basis of Allotment: | September 26, 2025 |
| Refunds: | September 29, 2025 |
| Credit to Demat Account: | September 29, 2025 |
| IPO Listing Date: | September 30, 2025 |
| IPO Bidding Cut-off Time: | September 25, 2025 – 5 PM |
| Particular | Shares | % Share |
| Promoter Holding Pre Issue | 50,00,000 | 100% |
| Promoter Holding Post Issue | 68,60,000 | 72.89% |
| Purpose | Crores | % |
| Capital Expenditure for Office Premises with furniture and Industrial Racks | 1.63 | -% |
| Working Capital | 8.00 | -% |
| General Corporate Purpose | – | -% |
| Period Ended | Revenue | Expense | PAT | Assets |
| 2023 | ₹13.90 | ₹13.60 | ₹0.19 | ₹6.22 |
| 2024 | ₹17.88 | ₹16.76 | ₹0.80 | ₹10.03 |
| 2025 | ₹24.64 | ₹20.44 | ₹3.10 | ₹21.92 |
| KPI | Values |
| ROE: | 44.50% |
| ROCE: | 45.66% |
| EBITDA Margin: | 19.31% |
| PAT Margin: | -% |
| Debt to equity ratio: | 1.49 |
| Earning Per Share (EPS): | ₹6.37 (Basic) |
| Price/Earning P/E Ratio: | N/A |
| Return on Net Worth (RoNW): | 44.50% |
| Net Asset Value (NAV): | ₹13.93 |
| Company | EPS | PE Ratio | RoNW % | NAV | Income |
| Zota health care limited | 3.16 | 382.12 | 2.72 | 110.83 | 261.90 Cr. |
| Sunrest Lifescience Limited | 4.66 | 10.56 | 12.36 | 37.72 | 33.12 Cr. |
| Lincoln Pharmaceuticals Limited | 41.11 | 13.53 | 12.26 | 335.34 | 645.71 Cr. |
| IPO Open Date | September 23, 2025 |
| IPO Close Date | September 25, 2025 |
| Face Value | ₹10 Per Equity Share |
| IPO Price Band | ₹65 to ₹70 Per Share |
| Issue Size | Approx ₹13.02 Crores |
| Fresh Issue | Approx ₹13.02 Crores |
| Issue Type | Book Built Issue |
| IPO Listing | BSE SME |
| DRHP Draft Prospectus | |
| RHP Draft Prospectus |